Stockscreener 앱 받기
6.45
5.56%
0.34
시간 외 거래:
6.45
전일 마감가:
$6.11
열려 있는:
$6.18
하루 거래량:
258.71K
Relative Volume:
2.17
시가총액:
$367.32M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-5.375
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
+16.64%
1개월 성능:
+58.87%
6개월 성능:
+30.70%
1년 성능:
+36.94%
1일 변동 폭
$5.98
$6.565
1주일 범위
$5.52
$6.565
52주 변동 폭
$2.60
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.45 | 347.95M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Pattern recognition hints at Design Therapeutics Inc. upside2025 Major Catalysts & Free Growth Oriented Trading Recommendations - Newser
Is Design Therapeutics Inc. stock trending bullish2025 Price Action Summary & Free High Return Stock Watch Alerts - خودرو بانک
tools to assess design therapeutics inc.’s risk profileTrade Analysis Summary & Weekly Top Performers Watchlists - Newser
Is Design Therapeutics Inc. stock influenced by commodity prices2025 Momentum Check & Capital Protection Trade Alerts - خودرو بانک
Design Therapeutics, Inc. shares rise 2.13% intraday after presenting at Cantor Biotech Equity Research. - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Using Bollinger Bands to evaluate Design Therapeutics Inc.Weekly Trend Recap & Low Risk Profit Maximizing Plans - Newser
Will Design Therapeutics Inc. continue its uptrendJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Design Therapeutics' Strategic Momentum in Gene Therapy: A Compelling Case for DSGN as a High-Growth Biotech Play - AInvest
Design Therapeutics' Pratik Shah Discusses GeneTAC Platform and Monogenic Diseases at Cantor Global Healthcare Conference 2025 - AInvest
Design Therapeutics’ Strategic Momentum and Growth Prospects in 2025 - AInvest
Is Design Therapeutics Inc. building a consolidation baseProfit Target & Advanced Swing Trade Entry Alerts - Newser
Long term hold vs stop loss in Design Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - Newser
Can Design Therapeutics Inc. expand its profit marginsRate Cut & Low Risk High Reward Trade Ideas - خودرو بانک
Can technical indicators confirm Design Therapeutics Inc.’s reversalTrade Volume Report & Short-Term High Return Ideas - Newser
Will Design Therapeutics Inc. benefit from AI trendsJuly 2025 Earnings & Comprehensive Market Scan Insights - خودرو بانک
Is Design Therapeutics Inc. a good stock for dollar cost averagingJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - خودرو بانک
Using data models to predict Design Therapeutics Inc. stock movement2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
Published on: 2025-09-03 12:30:21 - Newser
Applying big data sentiment scoring on Design Therapeutics Inc.Bull Run & Consistent Return Strategy Ideas - Newser
Combining machine learning predictions for Design Therapeutics Inc.M&A Rumor & Technical Pattern Based Signals - Newser
Understanding Design Therapeutics Inc.’s price movementWeekly Profit Report & Safe Entry Point Identification - Newser
Historical volatility pattern of Design Therapeutics Inc. visualized2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Tools to assess Design Therapeutics Inc.’s risk profileMarket Trend Report & Fast Momentum Stock Entry Tips - Newser
Can swing trading help recover from Design Therapeutics Inc. lossesIndex Update & High Conviction Buy Zone Alerts - Newser
Is Design Therapeutics Inc. stock reversal real or fakeJuly 2025 Institutional & High Win Rate Trade Tips - Newser
Has Design Therapeutics Inc. formed a bullish divergenceTrade Entry Report & Smart Money Movement Tracker - Newser
Can a trend reversal in Design Therapeutics Inc. lead to recoveryPortfolio Gains Report & Safe Swing Trade Setups - Newser
Can Design Therapeutics Inc. deliver alphaJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Design Therapeutics, Inc. shares rise 3.98% intraday after Twist Bioscience collaboration for novel antibody-drug conjugates. - AInvest
Published on: 2025-09-02 20:32:38 - خودرو بانک
Is Design Therapeutics Inc. currently under institutional pressureMarket Growth Summary & High Conviction Buy Zone Picks - خودرو بانک
Twist Bioscience Collaborates with Synthetic Design Lab - Business Wire
Wellington Management Group LLP Purchases Shares of 141,519 Design Therapeutics, Inc. $DSGN - Defense World
Is Design Therapeutics Inc.’s ROE strong enoughQuarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Is it too late to sell Janux Therapeutics Inc.Treasury Yields & Community Verified Trade Alerts - Newser
Visual trend scoring systems applied to Design Therapeutics Inc.Forecast Cut & Stock Market Timing Techniques - Newser
Will breakout in Design Therapeutics Inc. lead to full recoveryJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):